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Population-based, prospective longitudinal cohort studies are considering the issues surrounding returning findings
to individuals as a result of genomic and other medical research studies. While guidance is being developed for
clinical settings, the process is less clear for those conducting longitudinal research. This paper discusses work
conducted on behalf of The UK Cohort and Longitudinal Study Enhancement Resource programme (CLOSER) to
examine consent requirements, process considerations and specific examples of potential findings in the context of
the 1958 British Birth cohort. Beyond deciding which findings to return, there are questions of whether re-consent
is needed and the possible impact on the study, how the feedback process will be managed, and what resources
are needed to support that process. Recommendations are made for actions a cohort study should consider taking
when making vital decisions regarding returning findings. Any decisions need to be context-specific, arrived at
transparently, communicated clearly, and in the best interests of both the participants and the study.
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Whether and how to return ‘findings’ to individuals as a
result of genomic and other medical research studies is
being examined by population-based, prospective longi-
tudinal cohort (hereafter ‘cohort’) studies. Many cohorts
are now preparing DNA samples and collecting genetic
data as part of their protocol and making these resources
available to the research community [1]. Researchers
accessing these samples and data are commonly con-
ducting whole exome sequencing and whole genome
SNP genotyping and analysis and finding information
that might or might not have been a part of their ori-
ginal investigation. As the number of genomic resources
increases, there is every expectation that the number of
individual genomic research findings (hereafter ‘find-
ings’) discovered will also increase [2,3].
There has been considerable debate surrounding the re-
turn of findings, but it is generally agreed that findings
meeting the requirements of analytic validity, clinical sig-
nificance and actionability should be considered for return.* Correspondence: sew40@le.ac.uk
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unless otherwise stated.Other considerations include whether the individual has
consented to receive findings, whether the findings are
confirmed independently, and the seriousness of the condi-
tion indicated and the possibility that the intervention will
improve the person’s health or lifestyle [4]. Findings that
are not likely to benefit the individual should not be
returned. In response, experts are working to develop prac-
tical guidance, for example, the American Council of Med-
ical Genetics and Genomics (ACMG) recommendations
address the feeding back of secondary findings from clin-
ical whole-exome and whole-genome sequencing studies
[5]. Their list of variants that should be returned has
helped crystallise thinking, but in this rapidly changing area
of science, lists such as these need to be fluid. Mutations
will be found for new conditions, added to those already
implicated in disease or found to not be the driver previ-
ously thought. As well, while markers, such as blood pres-
sure levels will be different at various times, a person’s
genotype is static and predictive throughout life. But even
though someone’s genes may not change, there may be
new signals, environmental influences or epigenetic condi-
tions that will influence how a mutation will manifest itself
phenotypically [6]. Therefore, even though a mutation is
present, a person may not suffer from the condition orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This is a special burden on the provision of findings – bal-
ancing the knowledge that there is a moral imperative to
give back findings that can be beneficial to individuals with
the difficulty in having sufficient or timely information,
such as validated data or consent, on which to base a deci-
sion that will convey that benefit.
The ACMG recommendations exclude research studies.
Similarly, the UK10K project management framework
outlines a process through which findings can be returned
to participants in their study of the role low-frequency
and rare genetic variants, but excludes those participants
from population cohorts [7]. They acknowledge that their
framework “…does not address the important issue of Ifs
in population-based collections” [7]. This points to the
fact that the feedback of findings in a clinical setting is
very different from that for a research-focussed cohort.
An individual’s health and well-being may be significantly
improved by receiving findings, and this supports the
argument for providing these to research participants.
Returning findings can show respect to participants
and demonstrate reciprocity for their participation [8].
However, while clinical studies can create generalizable
research results as well as provide care for patients,
the goal of research cohorts to build and maintain a
resource for future research investigations.
Many long-standing cohorts that have a ‘no returns’
policy are now re-examining their position on return-
ing findings [9]. The UK Cohort and Longitudinal Study
Enhancement Resource programme (CLOSER) comprises
nine studies: the MRC National Survey of Health and
Development or 1946 cohort, the National Child Devel-
opment Study or 1958 British Birth cohort (1958BC), the
1970 British Birth cohort, Understanding Society, the
Hertfordshire Cohort Study, the Southampton Women’s
Survey, the Millennium cohort, Avon Longitudinal Study
of Parents and Children and the Life Study. All of these
cohorts recruit ‘healthy’ volunteers, whose samples and
associated data form a resource for future specified and
unspecified research. With an increasing probability of
discovering clinically significant findings at an individual
level, CLOSER recognised the need to examine the latest
evidence and guidance that could help their individual
studies to form future policy on this issue.
We suggest that there are two main sets of deci-
sions that need to be made by the leaders of cohort
studies when examining this issue. First, whether it is
ever appropriate to feed back findings. Second, if it is
decided that individual-level findings could or should
be returned in some circumstances, an appropriate
feedback process needs to be chosen. This paper pre-
sents existing guidance available to cohorts, examines
the process issues, and suggests a framework to assist
cohorts to make informed policy choices.Analysis
As part of the infrastructure development and support
programme 58READIE (Realising Easy Access to Data
and Infrastructural Enhancement) of 1958BC, one of us
(SEW) was asked to examine the pertinent issues to help
inform future best practice. The 1958BC was chosen as
an example of a cohort that was reconsidering its exist-
ing policy in the light of advances in genetic research.
Members of this cohort were born in Scotland, England,
and Wales during one week in 1958. The study has its
origins in the Perinatal Mortality Survey, but over the
subsequent nine surveys of members, or ‘sweeps’, the
study has collected a broad range of data in a number of
different domains including physical and mental health,
health behaviours, education, employment, fertility, fi-
nances, social participation, values and attitudes.
In the 2002/3, 1958BC conducted a biomedical sweep,
where samples of blood and saliva and associated data
were collected from approximately 9,000 cohort mem-
bers. This data forms part of the widely-accessed Well-
come Trust Case Control Consortium [10]. In order to
examine access to 1958BC DNA, one of us (NW) com-
piled a list of approved applications. Some projects had
found rare variants and there was the potential for find-
ings that might be considered for return. This provided
an opportunity to examine specific findings and the impli-
cations if they were fed back to participants. This led to a
targeted examination of the current position of the
1958BC, the current UK policy landscape, and the impli-
cations and considerations for a possible change in policy.
Examples from the approved applications list were
used to forecast the kinds of findings that the 1958BC
might need to consider returning. Based on these, we
reviewed the scientific literature to determine the impli-
cations disclosing this information to individuals. Only
findings pertinent to 1958BC members (now aged 56)
were considered. Other kinds of findings were excluded,
such as those from MRI scans which are discussed else-
where [11]. The existing consent materials from the
1958BC were examined to confirm current policy. To
set this policy in context and to confirm current prac-
tice, we conducted a review for policies and guidance
specific to the disclosure of findings, as well as the eth-
ical debates, which a cohort study in the UK could use
to inform its deliberations regarding a policy change.
Only those written or translated in English and devel-
oped between 1995 and 2014 were considered. A brief-
ing paper was presented and discussed at a CLOSER
meeting in July 2012 [12].
Existing policy and guidance on feeding back individual
level genetic findings in cohorts
There is currently little guidance for researchers con-
ducting longitudinal research, but some resources are
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In the UK, the Wellcome Trust and the Medical Re-
search Council, in their Framework for the return of
health-related findings, detail best practices and present
case studies to suggest approaches researchers use to
craft an appropriate feedback policy [13]. They recom-
mend that findings be fed back when the potential bene-
fits to an individual outweigh the potential harms, and if
it is feasible to do so. Where findings will be fed back re-
searchers should, “…develop a practical feedback path-
way that is adequately resourced” [13]. If findings will
not be returned, the reasons need to be clearly detailed
and justified.
The Public Population Project in Genomics and Soci-
ety (P3G) considered the return of varying categories of
findings specifically in the context of population-based
studies [1]. For these studies, traditionally, there has
been feedback of results from assessments taken at the
time of recruitment and storage of samples, and of gen-
eral research results in the form of newsletters or web-
sites [14]. The P3G statement stresses that any decisions
regarding returning individual findings must be made in
the specific context of each individual study and that, for
some population-based studies, not returning findings,
“…remains a viable option where appropriate” [1]. If an
existing ‘no return’ policy is to be changed, the possibil-
ity of returning findings could be raised with partici-
pants if they are being re-contacted, perhaps for consent
to participate in further research studies.
While the P3G statement addresses this issue at a gen-
eral or conceptual level, others have examined the prac-
tical issues [15]. Implementation issues need to be
considered, such as the need to re-confirm findings in-
dependently to ensure their accuracy, as well as to con-
firm the identity of the participant; legal responsibilities
of secondary researchers, as well as the resource man-
agers; and practicability and cost implications. Bledsoe
et al. stress that each biobank needs its own policies and
suggest that, if appropriate, an “…ethically defensible
plan…” should be submitted to their ethics committee
[15]. They advocate the position that “…return of indi-
vidual research findings be considered on a case-by-case
basis based on an evaluation of the risks and benefits to
individuals and costs to society” [15].
The salience of original consent and possibilities for
re-consent?
The consent materials for the genetic component of the
2002/3 biomedical sweep of the 1958BC stated that ‘no
information in the DNA will be given to [the partici-
pant].’ However, results from tests and measurements
taken at the time of assessment, such as blood pressure
and cholesterol readings, were reported to participants
via their general practitioners (GPs). This now raisesthree possibilities – continuing with a policy of non-
return of findings in line with original consents, returning
findings on an ad-hoc basis in contradiction to original
consent, or re-consenting those cohort members who had
originally provided blood samples for DNA extraction. Ex-
perts recommend that participants be re-consented,
governance-structure permitting, “…when the proposal
deviates significantly from what was stated in the initial
consent” [16].
The essential question is whether re-consent is a viable
option. Evidence shows that individuals, when asked, say
they want to have the choice to say yes or no to receiv-
ing findings [17], and by going through a re-consent
process, researchers are acting transparently and show-
ing respect for that participant’s contribution to the re-
search [18]. However, re-consenting participants to seek
a new use of their samples and data can have an impact
on a cohort, as opposed to re-contacting them for pur-
poses within the existing consent such as updating par-
ticipant information. Participants may be unwilling to
consent to the new terms and may withdraw. In prac-
tical terms, it may well not be possible to locate and
contact all of the respondents, particularly when the
study took place many years ago, again reducing num-
bers. Also, those who agree could be materially different
than those who do not, possibly introducing selection
bias due to over specific consent provisions (e.g. require-
ments such as the use of smartphone devices to partici-
pate that might only appeal to a certain segment of your
population) and potentially affect the representativeness
of results using the cohort [19]. Little work has been
done on the impact of re-consent on cohorts, but evi-
dence has shown that re-consent rates can be high. The
international MONICA (Monitoring trends and Deter-
minants in Cardiovascular Disease) project, in 2001,
sought permission to use existing blood samples for ‘aca-
demic’ genetic research. The response was good; 93% of
the 1409 participants agreed. However, the process itself
still cost the project 13% of its participants through non-
response and refusals [20]. A decision to try to re-
consent study participants would therefore not be taken
lightly and studies often seek the advice of an ethics
committee [21].
Which findings?
If a study decides that some individual-level findings
could or should be fed back to participants, a vital issue
becomes which ones should be returned. Even with
existing guidance, it can still be difficult to specify what
it actually means to meet the requirements for clinical
significance and actionability. It can be difficult to de-
velop guidelines which will be enduring because genetic
technologies and scientific knowledge are continually de-
veloping. We discuss examples appropriate to the 1958BC
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appropriate consents were in place.
Findings already in clinical practice that should be returned
Variants in genes or loci that have shown analytical val-
idity, clinical significance; and actionability should be
considered for return to individuals. One example, cited
by the ACMG and others [5,22], is familial hypercholes-
terolaemia (FH) which may be of relevance for studies
such as the 1958BC with members over the age of 45. FH
is a monogenic disorder that carries a high risk of prema-
ture coronary heart disease (>50% risk in men by age 50
and >30% in women by age 60); the estimated prevalence
in the UK population is 1 in 500 [23]. The disease is treat-
able by statins and lifestyle changes, but is currently under
diagnosed. UK NICE guidelines recommend against popu-
lation screening, but that a suspected case of FH should
be confirmed through genetic testing to confirm the diag-
nosis and to trigger cascade testing of relatives [23]. One
expert (E. Birney, personal communication) has estimated
that in a cohort such as the 1958BC of approximately
10,000, approximately 50 people will show a potentially
actionable mutation predisposing heart attack through
exome sequencing; a majority of these will be FH. Ap-
proximately 30-40 of these individuals will have their
diagnosis confirmed, triggering cascade testing leading
to 100-150 others to be approached regarding treat-
ment. Members of the 1958BC who have consented
will have had their cholesterol levels measured during
the 2002/3 biomedical sweep. It is unknown how many
1958BC members are actually predisposed, but based
on the above calculations, for a cohort its size, ap-
proximately 37 people could have a relevant mutation
(again with the majority being FH), 20-30 of whom
would have their diagnosis confirmed, with 75-100 fur-
ther family members to be tested (i.e. through cascade
testing). While there are currently no plans to exome
sequence the 1958BC, many SNPs in the exome, in-
cluding some of those targeted in FH testing, will have
been measured as part of the current UK exome chip
consortium and await analysis.
This argues for providing this information to those
1958BC members who have the mutation as there are
existing clinical services available and should not require
additional resources from the cohort. But, as has been
argued (E. Birney, personal communication), members
of the 1958BC may have already been diagnosed through
regular clinical procedures. Additionally, if indicators of
this disease were discovered at assessment for the bio-
medical sweep, individuals would have been advised to
seek confirmation from a medical practitioner. But not
everyone with the genetic mutation will suffer from the
condition. Is the benefit to a relatively few individuals of
knowing their FH status, which might be found otherwise,sufficient to impose a change of policy and the potential
impacts of that change?
The unclear status of rare and preliminary findings
It is less easy to decide whether other classes of findings
should be given back, such as rare mutations and widely
available preliminary findings. One example studied in
the 1958BC is the NC_012920.1 mutation (also known
as the m.1555A > G test), which can predispose individ-
uals to be hypersensitive to aminoglycosides [24], used
to treat infections such as multi-resistant strains of
Escherichia coli [25]. Treatment with drug levels in the
therapeutic range can cause profound and permanent
deafness for individuals with this mutation. It may also
cause late-onset hearing loss even in those not exposed
to aminoglycosides. One in 400 of the 1958BC members
tested showed the mutation and there was no evidence
of hearing loss in middle age in the 1958BC [24]. However,
Rahman et al., after studying the 1958BC, recommended
that while population-level screening is not indicated, pa-
tients should have genetic testing for NC_012920.1 prior to
aminoglycoside administration in order to prevent inevit-
able hearing loss.
One can see potential benefit in returning this infor-
mation. If a 1958BC member knew of their mutation
they could request confirmatory genetic testing prior to
administration or simply request that they not be given
aminoglycosides. But the actual number of people with
the NC_012920.1 variant is small and aminoglycosides
are currently not widely used, except in acute settings.
Providing this information to people could cause them
to worry about a situation that they may never face. Al-
ternatively, individuals could suffer severe medical com-
plications if such as finding is not given to them.
Because of the potential for distress in either case,
careful consideration would needed on whether, and
how, to give this information.
Widely available preliminary findings, such as for
coeliac disease, would most likely fall into the category
of those findings that are low risk with clinical validity,
and might be of some use to some individuals [22].
There is doubt regarding the precise phenotype for this
condition and more work is needed to determine exactly
which genes are causal [26]. But cohort members might
want this information, as changes in lifestyle can im-
prove the quality of life for sufferers. The cohort would
need to weigh up the costs and benefits of providing in-
dividual feedback on these findings in this category.
Infrastructure considerations
The return of individual-level findings is a complex issue
with the potential to dramatically impact an individual’s
life and any processes need to be well-considered to be
beneficial for those involved. If at least some findings are
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need to consider is how to decide on which findings to
return, how those findings will be returned, for how long
the cohort will take responsibility for returning findings,
and how these processes will be monitored and evalu-
ated. Crafting a sensitive and appropriate process will
show respect for the participation of cohort members, as
well as for the cohort as a scientific study.
Reaching a consensus on which findings to feedback
has been shown to be a difficult task as opinions differ
and evidence may be lacking [2,27]. Table 1 shows some
of the various options cohorts might have to assist them.
It has been suggested that cohorts only give back find-
ings that are already being treated in clinical practice
[11]. Outside experts could be approached [28], or co-
horts might join together to share common practice. In
this latter case, studies need to be very similar, so that
knowledge can be shared effectively. Existing resources
are available to assist, such as the variants listed in the
ACMG recommendations [5] or those from publically-
available online resources, such as The Personal Genome
Project GET-Evidence system or the Clinical Genomic
Database [29,30]. Time and expertise will be needed to
ensure that any list meets the needs of the cohort and is
not simply a way to show that a response has been made
to this important issue. As time passes and the science
changes, cohorts will have the opportunity to monitor
how their process is working. The input and experiences
of participants will help to inform and potentially modify
how approaches are taken. Reporting on these delibera-
tions could add to the empirical evidence which will
help others. Decisions on how long feedback of findings
will continue, such as only for the lifetime of the study,
will need to be taken and the reasons and implications
discussed with participants.
When secondary researchers outside the cohort report
findings, the important issues of communication and val-
idation need to be considered. Losing information, giving
incorrect information, or withholding correct information,Table 1 Options for routes through which cohort can make p
Options Advantages
Only return findings currently used
in clinical practice
Clear utility for participants; no need
for additional decision making body
Create own expert committee to
decide upon which findings to
return
Study-specific; greater control over
decision making process
Join other cohorts to form a joint
committee
Greater combined expertise; shared
costs
Rely on the committee of another
cohort
Inexpensive; no need for additional
decision making body
Rely on resources (i.e., lists or
databases) created by other expert
groups
Based on the latest evidence;
freely-available resources now
availablecould have serious implications for all those involved
[7,31]. To confirm findings, secondary researchers could
be asked to re-analyse materials, validation be done in-
house by the cohort, or outsourced to an independent la-
boratory for a second opinion using a DNA sample from
the same participant if available [32]. Appropriate measures
will help to avoid the potential of causing unnecessary dis-
tress through poor management. As with participants, sec-
ondary researchers will also need to be clear as to how long
they will be responsible for returning findings. They might
expect their responsibilities to end at the conclusion of
their own funded study and agreed use of the cohort data,
yet the cohort study will most likely be still in place. If the
cohort has clear management procedures for receiving
and returning findings, this should enable secondary
researchers to be in contact with information when
necessary.
Respecting an individual’s right to know and their right
not to know are important ways of showing respect for
autonomous decision making. Through a re-consent ex-
ercise or in prospective consent materials for a new
study, participants will be able to record whether or not
they wish to be re-contacted with findings. Any decision
on overriding that decision needs to be based on
whether the benefit to the individual could outweigh
their potential distress in learning the information. Ad-
vice from an oversight committee, such as a research
ethics committee can help with such decisions [1].
Finally, participants will need help to cope, both clinic-
ally and emotionally, with any findings given to them.
This is of course particularly important in relation to
genetic findings that may have implications for other
members of the family. In a recent study, participants
said they preferred that health-related findings be given
to them in a face-to-face setting, and “…generally…from
someone with medical knowledge and expertise, who
could ensure the finding was followed-up appropriately:
usually a GP or a specialist healthcare professional” [17].
The Wellcome Trust/MRC Framework gives an exampleolicy decisions on which findings to return
Disadvantages
Need to keep abreast of changes in clinical practice
Potentially resource intensive (i.e., funds to staff/maintain committee,
time donated by members)
If studies are not similar, decisions may be divisive or not useful
Decisions may not be specific enough for own cohort; no power to
oversee/direct decision making process
Data may not be specific enough or appropriate for cohort; if fee-based,
could be expensive; need time/expertise to apply their data to own
cohort
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team who could review potential cases and deliver the
feedback; this would help participants adjust from being
a ‘healthy volunteer’ to someone in need of clinical care.
Alternatively, information could be passed directly to
the participant’s GP who would then contact them for a
consultation. This presupposes cohort members have a
relatively stable, on-going relationship with a GP or
practice which will not be the case for all. For whoever
delivers the findings, making the information ‘under-
standable’ is key, as explaining genetic risk to lay persons
can present difficulties [33] and it is vital that additional
distress is not caused due to clumsy communication.
Wolf et al. recommend that “[f]indings should be
returned in a form that is understandable to the [partici-
pant] and useful to a physician or other clinician, such
as a genetic counsellor…” [4].
It is impossible to estimate how many findings will be
discovered over the life of a cohort project such as the
1958BC, but regardless of the number, ensuring that
there is adequate funding to maintain the system will
help to ensure that individuals are given information in
a timely and appropriate manner. The costs related to
the return of findings and the subsequent care involved,
and how those costs will be covered will differ from
country to country and setting to setting, but limited
evidence shows that returning findings can be expensive
[34,35]. Secondary researchers could help with planning
by informing the cohort if they expect to obtain findings
of potential clinical significance to individuals. Some
funders are now asking for this information as part of
protocols [36,37]. Also, some costs could possibly be
passed on to the researchers in order to help fund the
process, perhaps through fees included in data access
agreements.
Is there an argument for not returning findings to cohort
members?
It has been suggested that population-based studies can
decide to not return findings [1]. This would help pre-
serve the distinction between research and healthcare
[38]. By returning findings, cohort research may begin to
resemble screening, but without the rigorous guidelines
designed to protect individuals. In addition, there could
be a cost to society through shifting resources from re-
search to individual care [15]. However, there is an argu-
ment that the positive impact on one person’s life
through the feedback of a finding should outweigh any
administrative costs or loss of membership for a cohort,
leading to finding new ways in which to balance the po-
tential benefits to individuals with the nature of longitu-
dinal research. Dynamic consent models, for example,
allow participants to state preferences for feedback [39],
although it has been argued that these could contributeto the conflation of healthcare and research in the minds
of participants [40].
For some studies there is one clear way to justify a de-
cision to not return findings – by ensuring that there
will be no findings to return. This can be done by refus-
ing to grant access for any analysis (most likely genetic)
that might produce clinically significant findings. This
would preserve studies like the 1958BC that began be-
fore the genomic revolution and may have only added
genetic studies recently. It is questionable whether limit-
ing potential research uses is ethically-defensible. But
equally, it is questionable whether a cohort successfully
supplying data for a wide range of research (i.e., educa-
tional, social science and epidemiological research in the
case of the 1958BC) should be potentially damaged for
the sake of genetics.
Given that the original consents with members of the
1958BC explicitly stated that findings would not be
returned to cohort members, the team responsible for
this cohort has decided that individual findings will not
currently be returned. This will remain under review.
The team recognises that consents written a half a dec-
ade ago could not foresee the use of genomic analysis in
individual care. The next face to-face survey of the co-
hort is planned for 2018, when cohort members are aged
60, and an important part of the planning of this data
collection will be the decision about whether to re-
consent study members so that findings can be returned
in future. Indeed it may well be that it is decided to re-
collect DNA via saliva or blood at that time. The consid-
erations discussed in this paper, future guidance and evi-
dence from other cohorts will be very important for
informing the process of obtaining informed consent
that enables cohort members to decide whether they
wish to receive feedback on any findings, and will also
inform the structures and processes that would need to
be funded and put in place to support any return of
findings.
Conclusion
It is clear that people report that they want findings, “…
when a condition is serious and treatable”, [17] and want
to choose what findings to receive and how frequently
[41]. Whether these desires will in the future become
demands, potentially affecting recruitment and reten-
tion, is unknown. Any decisions made by a cohort will
need to be context-specific, arrived at transparently and
justifiable to its members. In particular, each cohort will
need to:
 Examine their consent provisions and decide if
consent is in place to return findings
 If consent is not in place, decide if it is necessary,
feasible, and in the best interests of scientific
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through a re-consent procedure; and if so, when.
 If findings are to returned, decide how the variants
to be returned will be chosen, how they will be
validated, confirmed and given to individuals.
 Write, and publically disseminate, a policy
statement, reflecting national and international best
practice guidance, that includes a list of the genetic
variants and how they were chosen (by whom and
using what criteria); the process that will be used to
return findings; and the responsibilities of the cohort
and of secondary researchers.
 Agree on an on-going monitoring programme, including
a periodic review of the list of variants, whether some
findings are appearing more frequently than others, and
whether the feedback process should be updated or
changed to ensure effectiveness.
 Ask cohort members, whether as research or
consultation, how the processes are working for
them and use that information to inform the
on-going review of policies and procedures.
Only through a transparent evidence-based examin-
ation of the issues will cohort study managers be able to
balance the needs of their members with the scientific
integrity of the cohort, in order to ensure the best inter-
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